ArticleJournal of clinical and translational hepatology2022
Liver Function Derangement in Patients with Severe Fever and Thrombocytopenia Syndrome.
Article in Journal of clinical and translational hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 16 citations in OpenAlex.
- Pre-existing immunity to heartland virus protects rhesus macaques from challenge with severe fever with thrombocytopenia syndrome virus.Emerging microbes & infections · 2026Article
- tRNA-derived small RNA, tsRNA-5017b, as a novel biomarker for predicting severity in severe fever with thrombocytopenia syndrome.Microbiology spectrum · 2026Article
- Aspartate aminotransferase-to-lymphocyte ratio predicts in-hospital mortality in patients with severe fever with thrombocytopenia syndrome: a multicenter retrospective cohort study.BMC infectious diseases · 2026Observational
- PCBP2 inhibits antiviral innate immune responses via the MAVS-mediated signaling pathway in severe fever with thrombocytopenia syndrome.Virus research · 2026Article
- Development of a Prophylactic mRNA Vaccine for Severe Fever with Thrombocytopenia Syndrome Using HSA based LNP.NPJ vaccines · 2026Article
- Article
- The holistic rehabilitation from acute severe fever with thrombocytopenia syndrome virus infection to 10 years after recovery: A cross-sectional study.Biosafety and health · 2025Article
- Lactate Dehydrogenase/Albumin to Urea Ratio: A Novel Prognostic Indicator for Adverse Outcomes in Patients With Severe Fever With Thrombocytopenia Syndrome.Journal of medical virology · 2025Article
- Prognostic nutritional index as an early predictor of mortality in patients with severe fever with thrombocytopenia syndrome: multicenter retrospective study in South Korea.BMC infectious diseases · 2025Article
- Characteristics and mechanisms of liver injury caused by emerging infectious diseases.Frontiers in immunology · 2025Review
- Causal relationship between hepatic function indicators and thrombocytopenia risk in early-stage hepatitis B virus infection: evidence from clinical observational studies and mendelian randomization analyses.Frontiers in immunology · 2025Observational
- Early identification of hepatocellular carcinoma patients at high-risk of recurrence using the ADV score: a multicenter retrospective study.World journal of surgical oncology · 2024Article
- Article
- Association of liver function and prognosis in patients with severe fever with thrombocytopenia syndrome.PLoS neglected tropical diseases · 2024Article
- Lactate dehydrogenase to albumin ratio (LAR) is a novel predictor of fatal outcome in patients with SFTS: an observational study.Frontiers in public health · 2024Observational
- The pathogenic and clinical characteristics of severe fever with thrombocytopenia syndrome patients with co-infections.Frontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Patients with severe fever with thrombocytopenia syndrome (SFTS) commonly show liver function impairment. This study aimed to characterize the liver function indices in SFTS patients and investigate their association with mortality. Methods: Clinical information and laboratory results of 459 laboratory-confirmed SFTS patients, including 78 deceased and 381 surviving patients, were retrospectively analyzed. To explore the infectivity of SFTS caused by novel Bunyavirus (SFTSV) in hepatocytes, Huh7 human hepatoma cells were infected with various concentrations of SFTSV Results: The proportion of SFTS patients developing liver injury during hospitalization was 73.2% (336/459); the hepatocellular injury was the predominant type. The median time to occurrence of liver injury from disease onset was 8 d. Liver injury in the deceased group occurred earlier than that in the surviving group. Alanine aminotransferase (ALT) level between 2-5 times upper limit of normal (ULN) at 4-6 d and between 5-15 ULN at 7-12 d of disease course were independent predictors of mortality. Alkaline phosphatase (ALP) >2 ULN at 7-9 d and elevated ALP at 10-12 days after disease onset were risk factors for death. ALT and aspartate transaminase (AST) levels were correlated with lymphocyte count and platelet-to-lymphocyte ratio (PLR). Total bilirubin (TB), ALT, AST levels showed positive correlation with viral load. In the Conclusions: Liver injury is common in SFTS patients. ALT and ALP were independent predictors of SFTS-related mortality. Frequent monitoring and evaluation of liver function indices are needed for SFTS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.